Invisicare
Invisicare20About
What does Invisicare do?
InvisiCare aimed to provide large-scale, low-cost preventive geriatric healthcare, addressing the global demographic challenge of population aging. They focused on developing eHealth technologies to improve care for the elderly, recognizing the limitations of existing mobile app, wearable, and smart home technologies.
What is Invisicare's revenue?
StartupHub estimates Invisicare's annual revenue at $173K (range $105K to $337K, 67% confidence), based on comparable companies in the sector.
When was Invisicare founded?
Invisicare was founded in 2017.
What industry does Invisicare operate in?
Invisicare operates in Healthcare, Senior Care, Assistant, HealthTech, Geriatric Care, Preventive Healthcare.
How many employees does Invisicare have?
Invisicare has approximately 1 people on record.
What is Invisicare's current status?
Invisicare's current operating status is: Inactive.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.